BridgeMD
Klonidin as pain relief in eye examination of premature infants - cloROP
EU CTIS ID: 2024-512438-14-00
What this study is testing
The primary objective is to investigate whether clonidine works is a good analgesic during examination for Retinopathy of Prematurity (ROP)
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- The infant is admitted to the study clinic
- The infants guardian/s has/have given their written consent to the child's participation in the study
- The infant is born before gestation week 30
You likely can't join if
- Children who has received beta blockers, pain reliever or sedating drug within 24 hours of eye examination.
- Previously documented kidney failure
- Does not have a gastric tube
- Neurologically affected
- Known cardiac arrhythmia
- Circulatory instability (defined as mean arterial pressure lower than the child's gestational age)
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0-17 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.